Figure 6.

In vivo anti-tumor effect of TKI258 in LoVo and HT-29 xenograft models. (A, B) After treating with the TKI258 (70 mg/kg/d PO for 4 weeks), the in vivo xenograft model showed that TKI258 delayed the growth of tumors induced by both cell lines compared with the control group (shown as Mean ± SE). However, when we precisely measured the differences in tumor volume in the control and drug-treated groups in a time-dependent manner, HT-29 xenografts appeared to be inhibited earlier than LoVo xenografts. Compared with the control groups, in the LoVo and HT-29 cell lines, tumor volume (C) and weight (D) decreased similarly following treatment with TKI258 in vivo.